The heat shock protein-90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms

PURPOSE: The clinical use of BRAF inhibitors is being hampered by the acquisition of drug resistance. This study demonstrates the potential therapeutic utility of the HSP90 inhibitor (XL888) in 6 different models of vemurafenib resistance. EXPERIMENTAL DESIGN: The ability of XL888 to inhibit growth...

Full description

Saved in:

Bibliographic Details
Main Authors:	Paraiso, Kim H. T., Haarberg, H. Eirik, Wood, Elizabeth, Rebecca, Vito W., Chen, Y. Ann, Xiang, Yun, Ribas, Antoni, Lo, Roger S., Weber, Jeffrey S., Sondak, Vernon K., John, Jobin K., Sarnaik, Amod A., Koomen, John M., Smalley, Keiran S. M.
Format:	Artigo
Language:	Inglês
Published:	2012
Subjects:	Article
Online Access:	https://ncbi.nlm.nih.gov/pmc/articles/PMC3398738/ https://ncbi.nlm.nih.gov/pubmed/22351686 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-2612
Tags:	Add Tag No Tags, Be the first to tag this record!

The heat shock protein-90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms

Similar Items